AirSculpt (AIRS) Q2 Revenue Falls 14%
AirSculpt Technologies (NASDAQ:AIRS), a company specializing in minimally invasive body contouring, released its second quarter fiscal 2025 results on August 1, 2025. The company reported GAAP revenue of $44.0 million in Q2 FY2025, a decline of 13.7% from the prior year quarter and fell short of analyst expectations of $45.45 million (GAAP). Diluted earnings per share (EPS) (GAAP) was a slight loss of $0.01, compared to the $0.01 GAAP earnings per share analysts had expected, but an improvement over the $0.06 GAAP net loss per share in Q2 2024. Adjusted EBITDA was $5.8 million, representing a decrease from $6.9 million in the same quarter last year. Despite ongoing declines in case volume and same-center performance, management reaffirmed its full-year 2025 revenue target of approximately $160 to $170 million and adjusted EBITDA target of approximately $16 to $18 million. The quarter showed incremental operational progress, such as narrowing the revenue decline and improving sequential results, but same-center demand remains under pressure.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
AirSculpt Technologies is best known for its patented AirSculpt® body contouring procedures. These treatments are minimally invasive and avoid needles, scalpels, and general anesthesia, aiming to deliver precise fat removal and skin tightening with quick recovery times. The company's model appeals to patients who want body shaping with less downtime and less discomfort compared to traditional methods.
Source Fool.com
